Last reviewed · How we verify
Rituximab (US)
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system. Used for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.
At a glance
| Generic name | Rituximab (US) |
|---|---|
| Also known as | Rituxan® |
| Sponsor | Amgen |
| Drug class | Monoclonal antibody (anti-CD20) |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
Rituximab targets CD20, a surface antigen expressed on B lymphocytes. By binding to CD20, it triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B cell depletion. This mechanism reduces autoimmune responses and is effective in B-cell malignancies and autoimmune disorders.
Approved indications
- Non-Hodgkin's lymphoma (B-cell)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
Common side effects
- Infusion reactions
- Infections
- Cytopenias (anemia, thrombocytopenia, neutropenia)
- Fatigue
- Fever
- Nausea
Key clinical trials
- Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma (PHASE1)
- Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (PHASE1, PHASE2)
- A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (PHASE3)
- A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products (PHASE3)
- MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis (PHASE3)
- Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (PHASE3)
- PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (PHASE3)
- Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab (US) CI brief — competitive landscape report
- Rituximab (US) updates RSS · CI watch RSS
- Amgen portfolio CI